Nasdaq:AMRXPublished
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
European Commission approval follows UK MHRA authorization of Adcomfo in March 2026 U.S. application for proposed biosimilar of XOLAIR® currently under review BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc.